One very strong reason to doubt that heavy metals, such as lead or mercury, play a large role in the meth crisis, is that heavy metal poisoning has telltale signs and symptoms that would not go unnoticed. Furthermore, we have excellent methods for the determination of Pb and Hg in the bloodstream, and there simply isn't any corresponding epidemic of heavy metal poisoning.
Also, a nitpick: the author refers to the condensation product of benzaldehyde and nitroethane, which is phenyl-2-nitropropene, abbreviated P2NP, incorrectly. He calls it "nitrostyrene (NTS)", which is the one-carbon-shorter homolog.
The other thing to keep in mind is that higher production volumes mean longer supply chains, and with illegal drugs longer supply chains mean more cuts (usually sugars, rarely toxic per se), and more cuts means an increased variance in the potency of the retail product, and variance in potency leads to users accidentally taking more than they intended to. The toxic effects of most drugs have a supralinear dose-response relationship, so these unexpectedly high doses can lead to problems that don't "average out". Often we over-focus on toxic fillers, but forget the risks created even by nontoxic fillers.
> Also, a nitpick: the author refers to the condensation product of benzaldehyde and nitroethane, which is phenyl-2-nitropropene, abbreviated P2NP, incorrectly. He calls it "nitrostyrene (NTS)", which is the one-carbon-shorter homolog.
Can you give a bit more detail about what's wrong here, and how it might be fixed? Are all mentions to nitrostyrene/NTS incorrect? This is used repeatedly in the cited papers, so I'm confused if they are also wrong, or the post has mangled usage, or what.
"Nitrostyrene" is sometimes used to refer to the whole class of chemicals featuring the phenyl-ethylene-nitro linkage. So it's not wrong to call it "the nitrostyrene method". But the specific nitrostyrene that is a precursor to methamphetamine is 1-phenyl-2-nitro-propene, while the parent compound "nitrostyrene" is 1-phenyl-2-nitro-ethene.
Also, a nitpick: the author refers to the condensation product of benzaldehyde and nitroethane, which is phenyl-2-nitropropene, abbreviated P2NP, incorrectly. He calls it "nitrostyrene (NTS)", which is the one-carbon-shorter homolog.
The other thing to keep in mind is that higher production volumes mean longer supply chains, and with illegal drugs longer supply chains mean more cuts (usually sugars, rarely toxic per se), and more cuts means an increased variance in the potency of the retail product, and variance in potency leads to users accidentally taking more than they intended to. The toxic effects of most drugs have a supralinear dose-response relationship, so these unexpectedly high doses can lead to problems that don't "average out". Often we over-focus on toxic fillers, but forget the risks created even by nontoxic fillers.